Definium Therapeutics, Inc. Comprehensive Income
Definium Therapeutics, Inc. (DFTX) reported Comprehensive Income of -$159.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$159.39M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$77.36M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$50.35M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$67.07M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$183.53M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$108.20M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$96.02M.
- Definium Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$57.22M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 7 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$159.39M 10-Q · filed 2026-08-06 | -$236.75M 10-Q · filed 2026-08-06 | -$287.10M derived: sum of 3 quarters · filed 2026-08-06 | -$354.18M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$77.36M 10-Q · filed 2026-08-06 | -$127.71M derived: sum of 2 quarters · filed 2026-08-06 | -$194.78M derived: sum of 3 quarters · filed 2026-08-06 | -$237.52M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$50.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$117.42M derived: sum of 2 quarters · filed 2026-02-26 | -$160.16M derived: sum of 3 quarters · filed 2026-08-06 | -$183.53M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$67.07M 10-Q · filed 2025-11-06 | -$109.81M derived: sum of 2 quarters · filed 2026-08-06 | -$133.18M 10-Q · filed 2025-11-06 | -$167.92M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$42.74M 10-Q · filed 2026-08-06 | -$66.10M 10-Q · filed 2026-08-06 | -$100.85M derived: sum of 3 quarters · filed 2026-08-06 | -$114.54M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$23.36M 10-Q · filed 2026-08-06 | -$58.11M derived: sum of 2 quarters · filed 2026-08-06 | -$71.80M derived: sum of 3 quarters · filed 2026-08-06 | -$77.66M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | -$34.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$48.44M derived: sum of 2 quarters · filed 2026-02-26 | -$54.30M derived: sum of 3 quarters · filed 2026-02-26 | -$108.20M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$13.70M 10-Q · filed 2025-11-06 | -$19.55M derived: sum of 2 quarters · filed 2025-11-06 | -$73.46M 10-Q · filed 2025-11-06 | -$97.76M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$5.86M 10-Q · filed 2025-11-06 | -$59.76M 10-Q · filed 2025-07-31 | -$84.06M derived: sum of 3 quarters · filed 2025-11-06 | -$101.57M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-03-31 | -$53.91M 10-Q · filed 2025-11-06 | -$78.20M derived: sum of 2 quarters · filed 2025-11-06 | -$95.71M derived: sum of 3 quarters · filed 2025-11-06 | -$125.12M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2023-12-31 | -$24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$41.81M derived: sum of 2 quarters · filed 2025-03-06 | -$71.22M derived: sum of 3 quarters · filed 2025-03-06 | -$96.02M 10-K · filed 2025-03-06 | |
| 2023-09-30 | -$17.51M 10-Q · filed 2024-11-07 | -$46.92M derived: sum of 2 quarters · filed 2024-11-07 | -$71.72M 10-Q · filed 2024-11-07 | -$76.74M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | -$29.41M 10-Q · filed 2024-08-13 | -$54.21M 10-Q · filed 2024-08-13 | -$59.23M derived: sum of 3 quarters · filed 2024-08-13 | -$75.82M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$24.80M 10-Q · filed 2024-05-08 | -$29.82M derived: sum of 2 quarters · filed 2024-05-08 | -$46.41M derived: sum of 3 quarters · filed 2024-05-08 | -$63.52M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$21.61M derived: sum of 2 quarters · filed 2024-02-28 | -$38.72M derived: sum of 3 quarters · filed 2024-02-28 | -$57.22M 10-K · filed 2024-02-28 | |
| 2022-09-30 | -$16.59M 10-Q · filed 2023-11-02 | -$33.70M derived: sum of 2 quarters · filed 2023-11-02 | -$52.20M 10-Q · filed 2023-11-02 | -$68.64M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$17.10M 10-Q · filed 2023-08-03 | -$35.60M 10-Q · filed 2023-08-03 | -$52.05M derived: sum of 3 quarters · filed 2023-08-03 | -$69.63M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | -$18.50M 10-Q · filed 2023-05-04 | -$34.95M derived: sum of 2 quarters · filed 2023-05-04 | -$52.53M derived: sum of 3 quarters · filed 2023-05-04 | -$97.07M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$16.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$34.03M derived: sum of 2 quarters · filed 2023-03-09 | -$78.57M derived: sum of 3 quarters · filed 2023-03-09 | -$92.27M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$17.58M 10-Q · filed 2022-11-10 | -$62.13M derived: sum of 2 quarters · filed 2022-11-10 | -$75.83M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$44.55M 10-Q · filed 2022-08-11 | -$58.25M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$13.70M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$33.65M 10-K · filed 2022-03-28 | ||||
| 2019-12-31 | -$10.70M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cronos Group Inc. (CRON) | $1.223B | ||
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B |